Clinical Evidence

GyroStim is indicated for the treatment of balance disorders and vestibular dysfunction. This indication supports its clinical use across a broad spectrum of neurological conditions shown to benefit from vestibular rehabilitation therapy (VRT), including concussion, TBI, stroke, Parkinsons, MS, cerebral palsy, ASD, POTS, and many other disorders affecting balance and sensorimotor integration.

Below is a summary of clinical evidence demonstrating GyroStim’s effectiveness in two of the most common conditions it treats—concussion and vestibular dysfunction.

Concussion / mTBI:

The clinical evidence presented below is the summary of a chart review of two groups of adult patients with a history of mTBI, loss of consciousness for less than 30 minutes, and with a current diagnosis of persistent post-concussion syndrome (PPCS). The chart review compares the outcome data of patients who received standard of care (SOC) with patients who received SOC and GyroStim multimodal technology-assisted neurorehabilitation.

Group 1: SOC
Patients in Group 1 received SOC treatment for PPCS / mTBI. Click here for details.
Group 2: SOC + GyroStim
Patients in Group 2 received the same SOC treatment as Group 1, but patients in Group 2 also received GyroStim neurorehabilitation. Click here for details.

All patients followed the same protocols for intake, balance education, and training for at-home daily therapy and exercise routines.
All patients were assessed with SCAT5 for pre and post intervention evaluation.
- SCAT5 (Sport Concussion Assessment Tool, 5th Edition) is a standardized, evidence-based assessment tool used to evaluate the presence and severity of concussion-related symptoms.
- The SCAT5 Symptom Severity Score has a total range from 0 to 132, where 0 indicates no symptoms and 132 represents the maximum possible symptoms.
All patients followed the same SOC treatment protocols for PPCS.
Group 2 received GyroStim neurorehabilitation treatment for PPCS, Group 1 did not.

Group 1: SOC

The SOC chart shows average scores from the SCAT5 assessment before and after SOC intervention.

Average pre-treatment SCAT5 score was 67.25
Average post-treatment SCAT5 score was 61
Average improvement (reduction in score) for SOC was 6.25 points.

Group 2: SOC + GyroStim

The SOC + GyroStim chart shows average scores from the SCAT5 assessment before and after SOC plus GyroStim intervention.

Average pre-treatment SCAT5 score was 86.5
Average post-treatment SCAT5 score was 34.75
Average improvement (reduction in score) for SOC plus GyroStim was 51.75 points.

SCAT5 Score Comparison

SCAT5 symptom severity score comparison reveals a significant difference in outcomes between Group1 and Group 2:

SCAT5 Symptom Severity Score
- Patients in Group 1 treated with SOC showed a relatively small clinical improvement in symptoms associated with PPCS / mTBI, as evidenced by an average SCAT5 score reduction (improvement in symptoms) of only 6.25 points.
- In contrast, patients in Group 2 treated with SOC + GyroStim showed a relatively large recovery from symptoms associated with PPCS / mTBI, as evidenced by an average SCAT5 score reduction of 51.75 points—more than 8 times greater than the SCAT5 score reduction of 6.25 points observed in Group 1.

The SCAT5 score comparison of Group 1 and Group 2 demonstrates that adding GyroStim therapy to SOC substantially increases effectiveness—accelerating recovery and delivering superior clinical outcomes compared to SOC alone.

Therapeutic Dose-Response Effect Comparison

Neurorehabilitation utilizes a multidisciplinary approach, with programs tailored to the unique needs of each patient. Consequently, treatment duration, number of sessions, and therapy frequency may vary across individuals. Therefore, therapeutic effectiveness is most accurately evaluated by calculating the therapeutic dose-response per session—the measurable average amount of recovery achieved with each multidisciplinary in-clinic therapy session.

The Therapeutic Dose-Response chart compares the average therapeutic dose-response per therapy session observed in Group 1 and Group 2.

Group 1 had an average of 20 SOC therapy sessions (in-clinic visits) with an average therapy frequency of 5.2 days over an average treatment duration of 104 days. The SCAT5 score change from the pre to post test shows a total average reduction in symptoms of 6.25 points, resulting in a relatively small therapeutic dose-response for SOC of 0.31 points per therapy session.
Group 2 had an average of 10 SOC + GyroStim therapy sessions (in-clinic visits) with an average therapy frequency of 8.2 days over an average treatment duration of 82 days. The SCAT5 score change from the pre to post test shows a total average reduction in symptoms of 51.75 points, resulting in a relatively large therapeutic dose-response for SOC + GyroStim of 5.18 points per therapy session.

The comparison between Group 1 and Group 2 shows that patients treated with SOC + GyroStim achieved approximately 17 X greater therapeutic dose-response than those treated with SOC alone. This demonstrates that integrating GyroStim with SOC produces a powerful enhancement to treatment—far more effective for recovering from PPCS than SOC alone.

Balance Comparison

Balance (mBESS)
- The Modified Balance Error Scoring System (mBESS) test has a scoring range of 0 to 30, with higher numbers indicating greater impairment in balance and postural control.
- The Balance chart demonstrates that patients in Group 2 (SOC + GyroStim) achieved an average balance improvement of 58%, compared to an average improvement of 23% observed in Group 1 (SOC only).

These findings indicate that the addition of GyroStim multimodal neurorehabilitation therapy substantially enhances postural control and balance outcomes compared to SOC alone.

Conclusion

Clinical evidence demonstrates that adding GyroStim multimodal neurorehabilitation therapy to SOC produces substantially superior outcomes for patients struggling to recover from PPCS.

Patients receiving SOC + GyroStim achieved an 8× greater reduction in symptom severity (SCAT5) and a 17× greater therapeutic dose-response compared to SOC alone. In addition, these patients demonstrated a 58% improvement in balance and postural control, more than double the improvement achieved by the SOC-only group.

This chart review provides clinical evidence that integrating GyroStim therapy into concussion and vestibular rehabilitation protocols significantly enhances treatment efficiency and effectiveness, accelerates recovery, and leads to more complete functional recovery than traditional therapies alone.

Balance Disorders and Vestibular Dysfunction

GyroStim-treated patients recovered five times faster than those receiving standard vestibular rehabilitation alone.

The Preliminary Clinical Data Comparison is a chart review comparing two groups of adult patients diagnosed with vestibular dysfunction. Based on the treatment received, the data was formed into two groups: Standard of Care (SOC) or GyroStim + Standard of Care (GS + SOC).

SOC = This group of patients were treated with targeted vestibular rehabilitation therapy (VRT) for vestibular dysfunction.
GS + SOC = This group received the same targeted VRT as SOC group, but this group also received GyroStim multimodal neurorehabilitation therapy for the treatment of vestibular dysfunction.

Both groups consisted of randomly selected adult patients diagnosed with vestibular dysfunction secondary to conditions including concussion/mTBI, stroke, BPPV, PPPD, vestibular neuritis, unilateral vestibular loss (UVL), bilateral vestibular loss (BVL), or mal de débarquement syndrome (MdDS).

All patients underwent identical standardized pre- and post-intervention assessments using validated, gold-standard clinical measures, including Sensory Organization Test (SOT), Dizziness Handicap Inventory (DHI), Activities-specific Balance Confidence Scale (ABC), and Modified Dynamic Gait Index (mDGI).

Both groups followed uniform protocols for intake procedures, balance education, and prescribed home exercise programs, ensuring comparability and consistency in the evaluation of treatment outcomes.

The comparison reveals significant differences in outcomes between the two groups:

Outcome Comparison
- Patients in the GS + SOC group demonstrated markedly faster recovery from vestibular dysfunction. Results from the Dizziness Handicap Inventory (DHI) assessment show that patients receiving GyroStim in addition to SOC achieved recovery in an average of 11 days, compared to an average of 56 days for those receiving SOC alone.
- These findings demonstrate that integrating GyroStim multimodal neurorehabilitation therapy with standard vestibular rehabilitation protocols significantly enhances treatment efficiency and clinical effectiveness, accelerates recovery timelines, and produces superior functional outcomes compared to standard of care alone for patients with vestibular dysfunction.